BioCentury on BioBusiness,
Politics and Policy
Makena for pre-term birth: How a low-priced drug became expensive
Related tables, figures and sidebars
Only the pricing is new
By Steve Usdin
Washington Editor
Published on
Monday, March 21, 2011
KV
Pharmaceutical Co. last week drew congressional attention over the
pricing of its newly approved Makena hydroxyprogesterone caproate to prevent
preterm birth in women with a history of preterm delivery.
The planned pricing - $1,500
per dose or $24,000-$30,000 per course of treatment - raised eyebrows because
the drug had previously been approved for use for more than 40 years, and KV
arguably has played a marginal role in getting it back on the market to replace
drug provided by compounding pharmacists for $10-$20 a dose.
86
words displayed of
1168
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]